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Abstract
The HIV epidemic has been continuously growing among women, and in some parts of the world, HIV-infected
women outnumber men. Women’s greater vulnerability to HIV, both biologically and socially, influences their
health risk and health outcome. This disparity between sexes has been established for other diseases, for example,
autoimmune diseases, malignancies and cardiovascular diseases. Differences in drug effects and treatment
outcomes have also been demonstrated.
Despite proven sex and gender differences, women continue to be underrepresented in clinical trials, and the
absence of gender analyses in published literature is striking. There is a growing advocacy for consideration of
women in research, in particular in the HIV field, and gender mainstreaming of policies is increasingly called for.
However, these efforts have not translated into improved reporting of sex-disaggregated data and provision of
gender analysis in published literature; science editors, as well as publishers, lag behind in this effort.
Instructions for authors issued by journals contain many guidelines for good standards of reporting, and a policy
on sex-disaggregated data and gender analysis should not be amiss here. It is time for editors and publishers to
demonstrate leadership in changing the paradigm in the world of scientific publication. We encourage authors,
peer reviewers and fellow editors to lend their support by taking necessary measures to substantially improve
reporting of gender analysis. Editors’ associations could play an essential role in facilitating a transition to improved
standard editorial policies.
Editorial
The HIV epidemic is increasingly affecting women, and
the proportion of women living with HIV globally has
been continuously on the rise. According to UNAIDS’
latest epidemic update, women constitute slightly more
than half of all people living with HIV. In sub-Saharan
Africa, women bear a disproportionate burden of HIV
infection: nearly 60% of adults living with HIV are
women, and young women, 15 to 24 years of age, are
eight times more likely to be infected than men in the
same age range. This trend is not restricted to sub-
Saharan Africa. Women living with HIV also outnumber
m e ni nt h eC a r i b b e a n .I nA s i a ,t h ep r o p o r t i o no fH I V
infections in women has been increasing: from 21% in
1990 to 35% in 2009. Similarly, the proportion of
women with HIV in countries where injecting drug use
has been the main driver of the epidemic has substan-
tially increased [1].
Biological and social differences between men and
women influence health risk and disease progression.
Women appear to be biologically more susceptible to
heterosexual HIV transmission partly due to the large
mucosal surface of the vagina and cervix as potential
viral entry points [2]. Other factors also suggested to
p l a yar o l ea r em i c r o - a b r a sion during sex, levels of
immunosuppression in the vaginal tract achieved by
seminal fluid, and morphological changes during the
hormonal cycle or hormonal fluctuations. In addition,
women can also be exposed through anal sex [3].
For a given CD4 cell count and disease stage [4], it
has been shown that women have a comparatively lower
level of virus, indicating that women may progress at a
lower viral load than men [5]. Furthermore, women
record higher CD4 cell counts at varying stages, includ-
ing seroconversion, AIDS diagnosis and death from
AIDS-related illnesses [6].
Despite evidence that antiretroviral drugs are equally
effective in women and men, different toxicity profiles
have repeatedly been reported. For example, in a recent
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ciated with stavudine-related toxicities [7]. Studies of
pharmacokinetics and pharmacodynamics of antiretro-
viral therapies (ARTs) have noted important variations
between women and men, demonstrating higher plasma
concentration in women as compared with men for sev-
eral drugs, including atazanavir, lopinavir, saquinavir,
nevirapine and efavirenz. Even differences in drug clear-
ance rate have been reported, for example, nevirapine
and saquinavir are shown to have a lower clearance rate
in women [8-10].
So far, these known differences have not translated
into different clinical management, with the exception
of nevirapine, which is not recommended for women
with CD4 cell counts above 250 cells/mm
3 due to a
higher risk of hepatotoxicity [11]. However, clinical
implications of such differences remain to be further
explored, and additional investigations are required to
fully map the sex-based differences in HIV disease pro-
gression, treatment outcome and clinical management.
It is important to note that in addition to physiological
and biological factors, social and behavioural factors play a
fundamental role in a person’s health and in the observed
health disparities between men and women. Women have
an increased vulnerability to HIV because of gender-based
p o w e rr e l a t i o n s :t h e ys u f f e rd o m e s t i ca n do t h e rg e n d e r -
based violence, and in gender-subordinate positions,
condom use is difficult, if not impossible, to negotiate
[12,13]. Together with socio-economic disadvantages,
such as illiteracy and poverty, these factors seriously
impede women’s access to testing, counselling, prevention
and treatment programmes.
Gender analysis is essential in demonstrating how
each sex’s biological processes interact with gender’s
social roles, socio-economic context, health-seeking
behaviours and access to healthcare systems. Such ana-
lyses are especially important in low-income countries
where gender differences in certain populations can
have dramatic effects on life choices and opportunities,
and in subpopulations, such as transgender people, who
are particularly vulnerable.
However, despite proven sex and gender differences,
women continue to be underrepresented in clinical
trials, and gender analyses of data continue to be con-
spicuous by their absence in published literature.
Women have historically been excluded from clinical
trials for a number of reasons. Concerns about causing
harm to the foetus have often been cited as the primary
reason. However, there are other contributing factors
that have practical implications. Desire to minimize het-
erogeneity in a study population is one. Studies powered
sufficiently to detect differences in subgroups would be
larger, more costly and less feasible (though not impos-
sible). Furthermore, hormonal variations during the
menstrual cycles introduce additional variables that may
complicate the analysis of the effect of a treatment [14].
Disregard of sex-specific data analysis and generaliza-
tion of research findings from one sex to another result
in interventions that are not firmly based on evidence
for efficacy in women and could potentially lead to sub-
optimal treatment and poorer outcomes. Ensuring parti-
cipation of women and other subpopulations, such as
transgender, in research, including collection and appro-
priate analysis of data, is crucial in drawing accurate
conclusions that can be applied to all subpopulations.
In 1993, following articulated concerns by women’s
health advocates about exclusion of women from clinical
trials, the US National Institutes of Health (NIH) issued
its revitalization act that mandates all NIH-funded clini-
cal trials to include women and minorities in adequate
numbers to be able to identify valid differences, if any,
between sexes and racial subgroups (USA, Public Law
103-43). The authors know of no such law or mandate
in other countries. Despite the effort by the NIH to
ensure rightful participation of subpopulations in trials,
women continue to be underrepresented in clinical
trials. In 2002, a study indicated that only 24% to 25%
of participants in many phase I and II clinical trials in
the United States were women [15]. A more recent
study, in 2006, showed that women remain underrepre-
sented in randomized controlled trials supported by US
federal funding. In 46 clinical studies that included both
male and female participants, women represented, on
average, 37% of the study population and only 24%
when limiting the analysis to drug trials [16].
In recent years, there has been an emergence of initia-
tives that advocate for gender mainstreaming in health
and life science research, in particular in the HIV field.
The UNAIDS initiative, “M a k eH I VT r i a l sW o r kf o r
Women and Adolescent Girls”, highlights the impor-
tance of establishing a “new norm” of research, where
women and adolescent girls are included in drug inter-
vention studies. In addition, data disaggregated by sex
and also age are key to this initiative as different factors
over a women’s lifespan need to be considered [17].
Resources that compile important information and
make access to knowledge more widely available are
gaining momentum. One such resource can be found
on the website, http://www.whatworksforwomen.org,
which “provides strategies and evidence on a full range
of gender-sensitive programming for women and girls”.
In 2010, on the occasion of International Women’s Day,
the International AIDS Society, jointly with 15 other orga-
nizations, including UN agencies, civil society partners and
pharmaceutical companies, released a Consensus State-
ment, “ASKING THE RIGHT QUESTIONS: Advancing
an HIV Research Agenda for Women and Children”.
The Consensus Statement highlighted 20 research
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efforts to fill these gaps. The statement called in particular
for research data “to be disaggregated by sex to ensure
opportunities for gender-based analysis using a variety of
indicators, such as retention in ART programmes, morbid-
ity and mortality, loss to follow-up, and pharmacokinetic
and pharmacodynamic parameters” [18].
On the occasion of International Women’s Day 2011,
we would like to encourage these efforts to be extended
to the world of scientific publishing. Despite increased
efforts and advocacy to include women and girls in clin-
ical trials, provision of sex-disaggregated data and gen-
der analysis in most published literature is rare and
often an exception to the rule. Geller et al showed that
87% of studies of randomized clinical trials published in
nine influential medical journals in 2004 “did not report
any outcome by sex or include sex as a covariate in
modelling” [16]. There is little evidence that the trend
has changed since then.
Increasing the involvement of women, and improving
the provision of gender analysis remains an urgent health
and women’s rights priority. Collection, analysis and
reporting of sex-disaggregated data are paramount in
ensuring that women and men have equal opportunities
to participate and enjoy the highest attainable standards
of physical and mental health; this is one of the funda-
mental human rights, as recognised in the Universal
Declaration of Human Rights and International Covenant
on Economic, Social and Cultural Rights.
Investigators, ethical review boards, funding bodies,
pharmaceutical industry, regulators, peer reviewers and
journal editors should play an active and leading role in
a broad range of aspects, from study design to guide-
lines and recommendations.
It is imperative that editors and publisher show bold
leadership in changing the paradigm in the world of
scientific publishing. Instructions for authors issued by
journals contain many guidelines for good standards of
reporting, and a policy on sex-disaggregated data and
gender analysis should not be amiss here. It is encoura-
ging to see high-profile journals take up this cause, such
as Nature raising this issue in June 2010 [19], although
concrete actions in this direction through formal
requirements in editorial policies have yet to be realized.
The Journal of the International AIDS Society is proud
to take a first step in this direction and feature such a
policy on its website (http://www.jiasociety.org/info/
about/) encouraging our authors to consider sex and
gender differences in their study designs and requiring
that gender analysis is presented in submitted manu-
scripts where applicable. Inclusion of this section in our
journal’s instructions for authors is currently under
negotiation with the publisher. We welcome peer
reviewers in lending their support by ensuring that the
aspect of gender is included in their overall assessments
of a manuscript and highlighting the absence of it when
necessary.
We call on fellow editors and publishers to take
appropriate measures to improve the reporting of sex-
based analyses in peer-reviewed publications. Editors’
associations play an essential role in continuously striv-
ing to improve standard editorial policies, and should
follow suit. Joint effort is necessary to ensure that
women, just as much as men, reap the fruits of research.
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